Venturi Wealth Management LLC grew its stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 20,421.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,746 shares of the company's stock after purchasing an additional 5,718 shares during the period. Venturi Wealth Management LLC's holdings in Doximity were worth $307,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. UMB Bank n.a. increased its stake in shares of Doximity by 69.1% in the 4th quarter. UMB Bank n.a. now owns 575 shares of the company's stock worth $31,000 after acquiring an additional 235 shares during the last quarter. GAMMA Investing LLC grew its position in Doximity by 20.6% in the 4th quarter. GAMMA Investing LLC now owns 1,735 shares of the company's stock valued at $93,000 after acquiring an additional 296 shares in the last quarter. MetLife Investment Management LLC grew its position in Doximity by 0.6% in the 3rd quarter. MetLife Investment Management LLC now owns 65,064 shares of the company's stock valued at $2,835,000 after acquiring an additional 363 shares in the last quarter. State of Alaska Department of Revenue grew its position in Doximity by 2.6% in the 4th quarter. State of Alaska Department of Revenue now owns 14,610 shares of the company's stock valued at $780,000 after acquiring an additional 370 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its stake in shares of Doximity by 22.5% in the 3rd quarter. First Horizon Advisors Inc. now owns 2,094 shares of the company's stock valued at $91,000 after buying an additional 384 shares during the period. Hedge funds and other institutional investors own 87.19% of the company's stock.
Doximity Trading Down 3.7 %
DOCS stock traded down $2.75 during trading on Friday, reaching $72.25. The stock had a trading volume of 3,202,946 shares, compared to its average volume of 2,419,548. Doximity, Inc. has a 1-year low of $22.96 and a 1-year high of $85.21. The company has a market capitalization of $13.49 billion, a P/E ratio of 72.25, a PEG ratio of 4.20 and a beta of 1.39. The firm has a fifty day moving average price of $59.79 and a 200 day moving average price of $48.73.
Insiders Place Their Bets
In other news, Director Timothy S. Cabral sold 20,000 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the completion of the sale, the director now owns 6,360 shares of the company's stock, valued at approximately $366,463.20. The trade was a 75.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 37.40% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on DOCS shares. Wells Fargo & Company lifted their price objective on Doximity from $43.00 to $55.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. Canaccord Genuity Group downgraded Doximity from a "buy" rating to a "hold" rating and upped their price target for the company from $40.00 to $60.00 in a report on Wednesday, November 13th. KeyCorp decreased their target price on shares of Doximity from $70.00 to $65.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Barclays increased their target price on shares of Doximity from $52.00 to $75.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. Finally, Bank of America lifted their price target on shares of Doximity from $54.00 to $57.00 and gave the company a "neutral" rating in a research report on Monday, January 6th. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $64.22.
Check Out Our Latest Stock Report on Doximity
About Doximity
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
See Also
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
